ASMB Key Statistics, Chart & Performance
The current stock price of ASMB is 33.99 USD. In the past month the price increased by 9.05%. In the past year, price increased by 111.78%.
ASMB Latest News, Press Relases and Analysis
ASMB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.74 | 396.55B | ||
| AMGN | AMGEN INC | 15.47 | 182.20B | ||
| GILD | GILEAD SCIENCES INC | 15.13 | 153.73B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.95 | 109.90B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.49 | 77.98B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 911.63 | 61.42B | ||
| INSM | INSMED INC | N/A | 44.06B | ||
| NTRA | NATERA INC | N/A | 32.66B | ||
| BIIB | BIOGEN INC | 10.76 | 26.43B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.97 | 20.42B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About ASMB
Company Profile
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. The company is headquartered in South San Francisco, California and currently employs 73 full-time employees. The company went IPO on 2010-12-17. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. The company is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Company Info
ASSEMBLY BIOSCIENCES INC
Two Tower Place, 7Th Floor
South San Francisco CALIFORNIA 94080 US
CEO: John G. McHutchison
Employees: 73
Phone: 18334094583
ASSEMBLY BIOSCIENCES INC / ASMB FAQ
What does ASSEMBLY BIOSCIENCES INC do?
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. The company is headquartered in South San Francisco, California and currently employs 73 full-time employees. The company went IPO on 2010-12-17. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. The company is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
What is the stock price of ASSEMBLY BIOSCIENCES INC today?
The current stock price of ASMB is 33.99 USD. The price increased by 0.3% in the last trading session.
Does ASSEMBLY BIOSCIENCES INC pay dividends?
ASMB does not pay a dividend.
What is the ChartMill technical and fundamental rating of ASMB stock?
ASMB has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is ASSEMBLY BIOSCIENCES INC (ASMB) stock traded?
ASMB stock is listed on the Nasdaq exchange.
Would investing in ASSEMBLY BIOSCIENCES INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ASMB.
ASMB Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ASMB. When comparing the yearly performance of all stocks, ASMB is one of the better performing stocks in the market, outperforming 96.27% of all stocks.
ASMB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ASMB. The financial health of ASMB is average, but there are quite some concerns on its profitability.
ASMB Financial Highlights
Over the last trailing twelve months ASMB reported a non-GAAP Earnings per Share(EPS) of -4.79. The EPS increased by 34.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -48.23% | ||
| ROE | -215.27% | ||
| Debt/Equity | 0 |
ASMB Forecast & Estimates
11 analysts have analysed ASMB and the average price target is 38.96 USD. This implies a price increase of 14.63% is expected in the next year compared to the current price of 33.99.
For the next year, analysts expect an EPS growth of 40.99% and a revenue growth 19.08% for ASMB